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PrognosisAbstract Background: Cerebrovascular stroke (CVS) is a common cause of death and disability.
The C-reactive protein increases in response to stroke and may be used as a predictor for stroke
outcome. We intended in this study to evaluate the role of serum CRP in predicting outcomes in
CVS.
Methods: We included 50 patients with a ﬁrst-ever acute stroke admitted within 24 h of onset
with a mean age of 59.5 ± 8.6 years. Neurological evaluation of our patients on admission included
assessment of stroke severity by the National Institute of Health Stroke Scale (NIHSS) while seven
days later; outcome was evaluated by a modiﬁed Rankin Scale (mRS) and Barthel ADL index (BI).
CRP level assay and CT brain were done to all patients on admission.
Results: In the ischemic stroke group, we found that serum CRP level on admission was predic-
tive of stroke severity (positively correlated with NIHSS (r= 0.54, P= 0.006)) as well as outcome
(positively correlated with mRS (r= 0.56, P= 0.004) and negatively correlated with BI
(r= 0.66, P< 0.001)). A CRP level of 10.25 mg/L was predictive of a severe ischemic stroke with
a sensitivity of 80% and a speciﬁcity of 75% as well as a poor outcome using mRS with a sensitivity
of 75% and a speciﬁcity of 82%. In hemorrhagic stroke, however, CRP level was not correlated
with either disease severity or with the outcome scores.
Conclusion: We concluded that the serum CRP level on admission can be used to predict severity
and early outcome in ischemic but not in hemorrhagic stroke.
Open access under CC BY-NC-ND license.
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Although Cerebro-vascular stroke is one of the leading causes
of death and disability in the elderly [1], indicators predicting
outcomes in such patients have not been clearly delineated.
Acute stroke may trigger an inﬂammatory response that
leads to increased levels of CRP [2]. This relationship between
inﬂammation and atherosclerosis makes CRP a potential prog-
nostic marker after vascular events and a potential predictor of
Table 1 The main items of the NIHSS.
Instructions Scale deﬁnition Score
1a. Level of consciousness: 0 = Alert
1 = Not alert; but arousable by minor stimulation to obey, answer, or respond
2 = Not alert; requires repeated stimulation to attend, or is obtunded and requires strong or painful stimulation
to make movements (not stereotyped)
3 = Responds only with reﬂex motor or autonomic eﬀects or totally unresponsive, ﬂaccid, and are ﬂexic
. . .. . ...
1b. LOC questions: The patient is asked the month
and his/her age. The answer must be correct
0 = Answers both questions correctly
1 = Answers one question correctly
2 = Answers neither question correctly
. . .. . ...
1c. LOC commands: The patient is asked to open and
close the eyes and then to grip and release the non-
paretic hand. Substitute another one step command if
the hands cannot be used.
0 = Performs both tasks correctly
1 = Performs one task correctly
2 = Performs neither task correctly
. . .. . ...
2. Best gaze: Only horizontal eye movements will be
tested. Voluntary or reﬂexive (oculocephalic) eye
movements will be scored, but caloric testing is not
done.
0 = Normal
1 = Partial gaze palsy; gaze is abnormal in one or both eyes, but forced deviation and total gaze paresis is not
present
2 = Forced deviation, or total gaze paresis not overcome by the oculocephalic maneuver
. . .. . ...
3. Visual: Visual ﬁelds (upper and lower quadrants)
are tested by confrontation, using ﬁnger counting or
visual threat, as appropriate. Patients may be
encouraged, but if they look at the side of the moving
ﬁngers appropriately, this can be scored as normal.
0 = No visual loss
1 = Partial hemianopia
2 = Complete hemianopia
3 = Bilateral hemianopia (blind including cortical blindness)
. . .. . ...
4. Facial palsy 0 = Normal symmetrical movements
1 =Minor paralysis (ﬂattened nasolabial fold, asymmetry on smiling)
2 = Partial paralysis (total or near-total paralysis of lower face)
3 = Complete paralysis of one or both sides (absence of facial movement in the upper and lower face)
. . .. . ...
5. Motor arm 0 = No drift; limb holds 90 (or 45) degrees for full 10 s
1 = Drift; limb holds 90 (or 45) degrees, but drifts down before full 10 s; does not hit bed or other support
2 = Some eﬀort against gravity; limb cannot get to or maintain (if cued) 90 (or 45) degrees, drifts down to bed,
but has some eﬀort against gravity
3 = No eﬀort against gravity; limb falls
4 = No movement
UN=Amputation or joint fusion, explain














6. Motor leg 0 = No drift; leg holds 30-degree posit for full 5 s
1 = Drift; leg falls by the end of the 5 eriod but does not hit bed
2 = Some eﬀort against gravity; leg fa to bed by 5 s, but has some
eﬀort against gravity
3 = No eﬀort against gravity; leg falls bed immediately
4 = No movement
UN= Amputation or joint fusion, exp in:
. . .. . ...
7. Limb ataxia 0 = Absent
1 = Present in one limb
2 = Present in two limbs
UN= Amputation or joint fusion
. . .. . ...
8. Sensory 0 = Normal; no sensory loss
1 =Mild-to-moderate sensory loss
2 = Severe to total sensory loss
. . .. . ...
9. Best language 0 = No aphasia; normal
1 =Mild-to-moderate aphasia
2 = Severe aphasia
3 =Mute, global aphasia; no usable sp h or auditory comprehension
. . .. . ...
10. Dysarthria 0 = Normal
1 =Mild-to-moderate dysarthria
2 = Severe dysarthria
UN= Intubated or other physical bar r, explain:. . .. . .. . .. . .. . .. . .
. . .. . ...
11. Extinction and inattention (formerly neglect) 0 = No abnormality
1 = Visual, tactile, auditory, spatial, o ersonal inattention or
extinction to bilateral simultaneous stim lation in one of the sensory
modalities
2 = Profound hemi-inattention or exti ion to more than one
modality; does not recognize own hand r orients to only one side of
space



























Table 2 The main items of the mR.
Score Description
0 No symptoms at all
1 No signiﬁcant disability despite symptoms; able
to carry out all usual duties and activities
2 Slight disability; unable to carry out all previous activities,
but able to look after own aﬀairs without assistance
3 Moderate disability; requiring some help, but able to walk
without assistance
4 Moderately severe disability; unable to walk without
assistance and unable to attend to own bodily needs without
assistance
5 Severe disability; bedridden, incontinent and requiring
constant nursing care and attention
6 Dead
Total (0–6) ––––




5 = Needs help cutting, spreading butter, etc.,




5 = Independent (or in shower)
GROOMING
0 = Needs to help with personal care




5 = Needs help but can do about half unaided
10 = Independent (including buttons, zips, laces, etc.)
BOWELS
0 = Incontinent (or needs to be given enemas)
5 = Occasional accidents
10 = Continent
BLADDER
0 = Incontinent (or catheterized and
unable to manage alone)




5 = Needs some help, but can do something alone
10 = Independent (on and oﬀ, dressing, wiping)
TRANSFERS (BED TO CHAIR AND BACK)
0 = Unable, no sitting balance
5 =Major help (one or two people, physical), can sit
10 =Minor help (verbal or physical)
15 = Independent
MOBILITY (ON LEVEL SURFACES)
0 = Immobile or <50 yards
5 =Wheelchair independent, including corners,
>50 yards
10 =Walks with help of one person
(verbal or physical) >50 yards
15 = Independent (but may use any aid;
for example, stick) >50 yards
STAIRS
0 = Unable
5 = Needs help (verbal, physical, carrying aid)
10 = Independent
TOTAL (0–100): ––––
46 M.A. Shoaeb et al.future vascular events. High levels of CRP may be associated
with poor outcome because they reﬂect either an inﬂammatory
reaction or tissue damage [3]. It is not clear whether this is due
to a direct effect or rather an epiphenomenon.
Elevated serum levels of CRP are found in up to three quar-
ters of patients with ischemic stroke [4]. Increases in CRP may
reﬂect a systemic inﬂammatory response following stroke, the
extent of tissue injury, or concurrent infections. Moreover, in
animal models of focal cerebral ischemia, CRP increases sec-
ondary brain damage through activation of the complement
system [5]. Less evidence is available for hemorrhagic stroke.
Plasma CRP was seen to increase shortly after admission
and was related to hematoma volume at later time points in
hemorrhagic stroke [6]. This was attributed to inﬂammatory
response to the hematoma [6].
The role of CRP as a marker during and after stroke is less
extensively studied in comparison to coronary artery disease.
The Rotterdam study shows that although high CRP is associ-
ated with the risk for future stroke, it is not useful for individ-
ual stroke prediction [7]. On the other hand, the Framingham
study shows that high CRP is associated with a greater risk for
ischemic stroke or TIA [8].
Several studies have assessed the value of CRP in the very
early phases of stroke as a prognostic factor of functional out-
come. Many of these studies evaluated only the relation be-
tween CRP and mortality instead of functional outcome.
The ﬁndings were inconclusive; some found a positive associa-
tion but others did not [9,10].
In search for further clariﬁcation of its role in cerebrovascu-
lar stroke, we sought to evaluate CRP level as an early prog-
nostic factor of functional outcome after stroke, as it is an
easily measured and a readily available inﬂammatory marker.
Aim of the study
This study was intended to evaluate the role of serum CRP as-
say within 24 h of stroke onset as a biomarker for predicting
disease severity and short term outcome (within 1 week).
Patients and methods
This prospective study included patients admitted with ﬁrst-
ever acute stroke within the ﬁrst 24 h of onset to the generalintensive care unit of the Damietta general hospital in the per-
iod from May 2012 to November 2012. We excluded patients
admitted more than 24 h after symptoms onset, patients with
recent history of traumatic brain injury, acute coronary syn-
drome, cerebro-vascular events, autoimmune disease, liver cell
failure, and chronic renal failure.
The study protocol was approved by the institutional re-
view board at Cairo University together with representatives
of study conduction site, and written informed consent to par-
ticipate and publish data were obtained from all participating
patients or ﬁrst degree relatives.
Patients included in the study were subjected to full history
taking with special emphasis on smoking index (number of cig-
arettes/day times number of years), hypertension (deﬁned as
Table 4 General characteristics in all patients.
Mean ± SD
Age (year) 59.5 ± 8.6
Smoking index 85.2 ± 157.2
Systolic blood pressure (mmHg) 181 ± 37
Diastolic blood pressure (mmHg) 108 ± 22
Mean blood pressure (mmHg) 132.1 ± 26.4
RBS (mg %) 237.1 ± 104.3
Cholesterol (mg/L) 227.2 ± 54.5
CRP (mg/L) 7.6 ± 4.9
CRP in cerebrovascular stroke 47treatment with antihypertensive medication or documented
blood pressure P140 mmHg systolic and/or P90 mmHg dia-
stolic), diabetes mellitus (deﬁned as treatment with antidiabet-
ics or diagnosis of diabetes during hospital stay), and
dyslipidemia.
Besides hemodynamic evaluation, neurological evaluation
included assessment of stroke severity by the National Institute
of Health Stroke Scale (NIHSS) and stroke was categorized as
mild (NIHSS 0–7), moderate (NIHSS 8–14), or severe (NIHSS
>14) [11,12]. Table 1 shows the main items of the NIHSS.
Seven days following the onset of stroke, we evaluated the
outcome of patients using two different scores including mod-
iﬁed Rankin Scale (mRS) [13–15] and Barthel ADL index (BI)
[16]. Poor outcome was considered to be >2 by mRS score
and <95 by BI. Tables 2 and 3 show the main items of the
mRS and BI, respectively.
A brain CT scan was done on admission to all patients to
differentiate between ischemic and hemorrhagic stroke.
Blood samples were withdrawn on admission for routine
laboratory tests and for CRP level assay. Three ml of venous
blood was taken through a venipuncture and sent coded by
the patient’s number to the laboratory. The lab was blinded
to the samples. The CRP assay was done using solid phase en-
zyme-linked immunosorbent assay. Normal reference of CRP
was less than 5 mg/L.
Statistical methods
Data were prospectively collected and coded prior to analysis
using the professional statistical Package for Social ScienceFigure 1 Presentation severity according to NIHSS and out(SPSS version 16). The description of data was in the form
of mean (±) SD for quantitative data and frequency and pro-
portion for qualitative data. Student-t Test (t) was used for
comparison between two groups regarding normally distrib-
uted (parametric) quantitative data. Chi-Square Test (x2) was
used for comparison between two groups regarding qualitative
data. Spearman correlation coefﬁcient test (r) was used to test
a positive or negative relationship between two variables. Re-
sults were considered signiﬁcant if P 6 0.05. A receiver operat-
ing characteristic (ROC) analysis was performed to deﬁne a
cut-off value of serum CRP for severe stroke and poor out-
come prediction and the associated speciﬁcity and sensitivity
levels.Results
This is a prospective study involving 50 patients admitted with
acute stroke within 24 h of onset. The mean age of our popu-
lation was 59.5 ± 8.6 years ranging from 45 to 75 years.
According to admission CT brain, our patients were classiﬁed
into two groups; Group A included 25 patients with acute
ischemic stroke (13 M, mean age 58.7 ± 9.3 years old) and
Group B involved 25 patients with hemorrhagic stroke
(13 M, mean age 60.3 ± 8 years old). Table 4 shows some of
the general characteristics of our population. Twenty patients
from hemorrhagic stroke group had spontaneous intracerebral
hemorrhage while ﬁve had subarachnoid hemorrhage.
Patients were categorized as mild stroke (NIHSS 0–7),
moderate (NIHSS 8–14), or severe stroke (NIHSS >14). Pa-
tient outcome was measured by mRS and BI seven days after
stroke onset. Poor outcome was deﬁned as mRS > 2 or
BI < 95.
Severity of stroke assessed by NIHSS revealed a mean score
of 13 ± 14 with 15 patients (30%) stratiﬁed as severe, 5 pa-
tients (10%) as moderate, and 30 patients (60%) as mild
(Fig. 1).
Outcomes assessed 7 days after admission by mRS revealed
a poor outcome in 22 patients (44%); however, outcome eval-
uation by BI revealed a poor outcome in 32 patients (64%).
The mean mRS for the whole population was 2.7 ± 2.2 and
the mean BI was 60.7 ± 41 (Fig. 1).come according to mRS and BI in the study population.
Table 5 Demographic data in both groups.
Ischemic stroke Hemorrhagic stroke P value
Age (year old) 58.7 ± 9.3 60.3 ± 8 0.5
Gender Male [N (%)] 13 (52%) 13 (52%) 1
Female [N (%)] 12 (48%) 12 (48%)
Diabetes mellitus [N (%)] 18 (72%) 18 (72%) 1
Dyslipidemia [N (%)] 9 (36%) 9 (36%) 1
Systolic blood pressure (mmHg) 154 ± 20 208 ± 30 P< 0.001
Diastolic blood pressure (mmHg) 92 ± 11 123 ± 19 P< 0.001
Mean Blood Pressure (mmHg) 113 ± 14 151 ± 22 P< 0.001
48 M.A. Shoaeb et al.There was a strong positive correlation between disease
severity assessed by NIHSS and outcome assessed by mRS
(r= 0.9, P< 0.001) and a strong negative correlation with
the outcome assessed by BI (r= 0.96, P< 0.001).
Serum CRP level on admission was positively correlated
with NIHSS (r= 0.337, P= 0.02), with mRS (r= 0.276,
P= 0.05), and negatively correlated with BI (r= 0.375,
P= 0.007).
The demographic characteristics of both groups of the
study are shown in Table 5.
Serum CRP level in group A was positively correlated with
NIHSS (r= 0.54, P= 0.006) (Fig. 2). Serum CRP level was
14.4 ± 6 mg/L in patients with severe ischemic stroke com-
pared to 7.7 ± 4.5 mg/L in patients with mild and moderate
presentation (P= 0.01). We detected a CRP level of
10.25 mg/L to predict severe ischemic stroke with a sensitivity
of 80% and a speciﬁcity of 75%. Patients of group B with hem-
orrhagic stroke showed that the admission CRP was however,
not correlated with stroke severity. We could not deﬁne any
correlation between serum CRP level and NIHSS (r= 0.31,
P= 0.1) (Fig. 3).
In ischemic stroke, SerumCRP on admission correlated pos-
itively with mRS (r= 0.56, P= 0.004) and negatively with BI
(r= 0.66, P< 0.001) (Fig. 4). Mean serum CRP level in pa-
tients with poor outcomes according to mRS was 13 ± 6.3 mg/
L compared to 7.1 ± 4 mg/L for patients with favorable out-
comes (P= 0.009) and it was 11.8 ± 5.4 mg/L in patients with
poor outcomes according to BI compared to 4.9 ± 1.6 mg/L in
patients with favorable outcomes (P= 0.001) (Table 6). UsingFigure 2 Correlation between CRPROC analysis, we detected a cut-off level of serumCRP level on
admission of 10.25 mg/L to predict poor prognosis using mRS
with a sensitivity of 75% and a speciﬁcity of 82% and a level of
6.95 mg/L to predict poor prognosis using BI with a sensitivity
of 80% and a speciﬁcity of 90%. In hemorrhagic stroke, there
was no correlation between CRP and mRS (r= 0.22,
P= 0.3) or BI (r= 0.24,P= 0.24) (Fig. 5). SerumCRP level
was 6.9 ± 4.6 mg/L in patients with poor outcome using mRS
in hemorrhagic stroke compared to 5.3 ± 2.5 mg/L in patients
with favorable outcome (P= 0.3) and it was 6.3 ± 4.4 mg/L in
patients with poor outcome using BI compared to
5.8 ± 2.6 mg/L in patients with favorable outcome (P= 0.7)
(Table 6).
Disease severity assessed by NIHSS was positively corre-
lated with mRS in both groups (r= 0.83, P< 0.001 and
r= 0.95, P< 0.001 for both groups, respectively) and nega-
tively correlated with BI (r= 0.93, P< 0.001 and
r= 0.97,P< 0.001, respectively). In ischemic stroke, NIHSS
was 25 ± 14.6 and 15.1 ± 15 in patients with poor outcome as-
sessed by mRS and BI, respectively, compared to 3.2 ± 1.1 and
2.7 ± 1 for patients with favorable outcomes (P< 0.001 and
P= 0.01 for mRS and BI, respectively). In hemorrhagic stroke,
it was 26.5 ± 12.1 in patients with poor outcomes using mRS
and it was 22.8 ± 13.7 in patients with poor outcomes using
BI compared to 2.3 ± 2.5 and 1 ± 1.4 in patients with favor-
able outcomes using mRS and BI, respectively (P< 0.001 for
both).
Comparing both groups together, CRP was signiﬁcantly
higher in ischemic stroke than in hemorrhagic stroke. CRPand NIHSS in ischemic stroke.
Figure 3 Correlation between CRP and NIHSS in hemorrhagic stroke.
Figure 4 Correlation between CRP and mRS and BI in ischemic stroke.
Table 6 CRP level in poor and favorable outcomes in both groups.
CRP level (mean ± SD) (mg/L)
Ischemic stroke P value Hemorrhagic stroke P value
mRS Poor outcome 13 ± 6.3 0.009 6.9 ± 4.6 0.3
Favorable outcome 7.1 ± 4 5.3 ± 2.5
BI Poor outcome 11.8 ± 5.4 0.001 6.3 ± 4.4 0.7
Favorable outcome 4.9 ± 1.6 5.8 ± 2.6
CRP in cerebrovascular stroke 49was 9 ± 5.5 mg/L in ischemic stroke compared to
6.2 ± 3.8 mg/L in hemorrhagic stroke (P= 0.039) (Fig. 6).
Discussion
Stroke is the third most common cause of death and the ﬁrst
leading cause of disability in developed and developing coun-
tries [17]. C-reactive protein is a glycoprotein produced by
the liver, and is normally absent in blood. The presence of
acute inﬂammation with tissue destruction within the body
stimulates its production. The CRP typically rises within 6 hof the start of inﬂammation, allowing the inﬂammation to be
conﬁrmed [18].
Atherothrombosis is the leading cause of stroke [19] and it
is now recognized that inﬂammation is central to the initiation,
development and rupture of atherosclerotic plaques [20]. The
recruitment of immune cells, such as macrophages and T-cells,
to plaques leads to the secretion of multiple inﬂammatory
mediators, including pro-inﬂammatory cytokines, free radicals
and proteases that ultimately promote plaque rupture and
thrombosis [20]. Brain damage whether ischemic or hemor-
rhagic stimulates the mobilization and migration of peripheral
Figure 5 Correlation between CRP and mRS and BI in hemorrhagic stroke.
Figure 6 CRP of both groups.
50 M.A. Shoaeb et al.immune cells, particularly neutrophils and macrophages, into
the brain and induces systemic inﬂammatory response [21,22].
We intended to evaluate the value of early serum CRP level
on admission as a biomarker for predicting stroke severity and
short term outcome in patients admitted with stroke.
We found in our study that the serum CRP is a predictor
for severity and outcome in ischemic stroke but not in hemor-
rhagic stroke. It was positively correlated with NIHSS and
mRS and negatively correlated with BI in ischemic stroke.
We found a serum CRP level of 10.25 mg/L to be 80% sensi-
tive and 75% speciﬁc to address severe ischemic stroke and to
be 75% sensitive and 82% speciﬁc to address poor outcome
using mRS.
The NIHSS was used in this study to evaluate the stroke
severity and was developed and validated for assessing the ini-
tial stroke severity [11,23]. Many studies showed that it is pre-
dictive of stroke outcomes [12,24–26]. Our study showed that
the NIHSS is a strong predictor for poor outcome in stroke pa-
tients whether ischemic or hemorrhagic, thus was in agreement
with other studies [12,24–26]. A study of ischemic stroke pa-
tients identiﬁed admission stroke severity as measured by
NIHSS score as the strongest predictor of 3-month mortality
[27] and another one concluded that it was the only indepen-
dent predictor of 30-day mortality [26]. All of these studies
evaluated the NIHSS in ischemic stroke. In our study, it was
a predictor for outcome in both hemorrhagic and ischemic
strokes.
We evaluated the clinical and biomarker variables in the
whole population and then in two groups of hemorrhagicand ischemic stroke patients. Serum CRP level was found to
be signiﬁcantly correlated with the stroke severity and outcome
irrespective of the type of the stroke. While subanalysing each
group separately, we found that the serum CRP level, mea-
sured within 24 h of stroke onset, was signiﬁcantly correlated
with disease severity and outcome in ischemic but not in hem-
orrhagic stroke. The signiﬁcant correlation between the CRP
and the severity and outcome in the whole population could
hence be explained by the strong correlation in the ischemic
stroke sub-population.
Many investigators have found a wide range of increase in
CRP after stroke [28,29]. Di Napoli et al. found that CRP con-
centration increased in the ﬁrst 24 h following stroke; this
increment was associated with the size of the infarction, so
mounting CRP levels in the ﬁrst 24 h were synchronized to
poor prognosis [29]. However, the same investigator in a later
work concluded that there is insufﬁcient evidence to justify the
routine use of CRP for either primary or secondary risk strat-
iﬁcation for cerebrovascular disease alone [30]. Some other
investigators also reported an association with mortality, but
functional outcome was not assessed [9].
The association between high CRP and a high stroke sever-
ity remains unexplained. Atherothrombosis of the cerebral ves-
sels is considered an inﬂammatory disorder with acute phase
reactant proteins produced in the ﬁrst few hours [18]. The de-
gree of inﬂammation determined by elevated CRP levels has
been associated with an increased risk of vascular complica-
tions [31]. There is a distinct possibility that elevated CRP is
a direct response to the extent of cerebral tissue injury [32].
As an inﬂammatory marker, it is possible that high CRP is
associated with underlying processes that cause more severe
strokes. Another link is the activation of coagulation by the
elevated CRP levels through the important role of tissue factor
expression [33]. Previous data showed that activation of coag-
ulation factors in stroke patients increased mortality, and
ﬁbrinogen has a putative role [34,35].
Interestingly, studies have shown that CRP itself may con-
tribute to secondary brain damage after focal cerebral ische-
mia, possibly via a complement-mediated exacerbation of
tissue injury [36]. It is therefore conceivable that increased lev-
els of CRP following stroke are not only a consequence of
brain infarction, but contribute to ischemic damage as well.
Whether high CRP causes more severe strokes or vice versa
needs to be further studied in larger population-based cohort
CRP in cerebrovascular stroke 51studies, or in clinical studies with very early measurements.
Precise knowledge of the possible triggers of inﬂammation
and the determinants of its individual response may open no-
vel therapeutic avenues. The absence of a crucial role of the
inﬂammatory process in the pathogenesis of hemorrhagic
stroke could explain the lack of the prognostic value of CRP
in this subgroup of patients. Contrary to this, some studies re-
vealed an association between elevated CRP and outcome in
hemorrhagic stroke including an association even with hema-
toma size in intracerebral hemorrhage [6] and an association
with the occurrence of vasospasm in aneurysmal subarachnoid
hemorrhage [37,38]. Spontaneous intracerebral hemorrhage
was seen to precipitate a complex cascade of cerebral and sys-
temic inﬂammatory response [39]. The acutely injured brain re-
leases large amount of interleukin-6 (IL-6) that is correlated
with severity of brain injury and prognosis [40]. Furthermore,
IL-6 is a major stimulus for hepatic production of CRP. The
inﬂammatory reaction in hemorrhagic stroke appears to be a
response to hemorrhage rather than a pathogenesis as in ische-
mic stroke. Accordingly, in acute ischemic stroke the CRP re-
sponse appears to be triggered quite rapidly [41]. This might
explain the lack of relation between CRP and outcome in hem-
orrhagic stroke as we measured serum CRP early on hospital
admission only.
We found in our study that the serum CRP level was signif-
icantly higher in ischemic stroke compared to hemorrhagic
stroke. Our results were in agreement with the results of other
researchers [42,43]. Again, this could explain the early role
played by the inﬂammatory process in the pathogenesis of
ischemic stroke more than in hemorrhagic stroke.
Our study has few limitations. Although the use of high
sensitivity CRP would have been more sensitive than the reg-
ular CRP, however, we thought to evaluate the commonly
present, readily available marker in most ICUs in our country
as a prognostic marker for cerebrovascular accidents. One lim-
itation is that we did not correlate the size of the hemorrhage
on CT examination with CRP, however, this could have been
an addition only if we have found a clinical correlation of the
hemorrhagic stroke with CRP, which we did not ﬁnd. More-
over, our study mainly aimed at ﬁnding a correlation between
the CRP and the clinical outcome rather than the radiologic
ﬁndings. Another limitation is the use of single CRP measure-
ment rather than multiple measurements which could have
been more informative about the later stages of the stroke,
however, our study aimed at evaluating the early predictive va-
lue of the biomarker.
Conclusion
Assessing CRP on admission is a predictor for severe disease
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